The Brain Aneurysm Foundation (BAF), a leading global research and advocacy organisation committed to improving treatment and care for brain aneurysms, has announced the addition of Carolina Maier—vice president of Clinical Affairs at RapidAI—to its board of directors.
“We are beyond thrilled to add someone of Carolina’s calibre to our board of directors,” said Christine Buckley, executive director and board president, BAF. “Her expertise in neuroscience and research will add great value to our current and growing research funding initiatives in a more global capacity. Her passion for the cause is unrivalled.”
Established in 1994, BAF is recognised as a global leader in brain aneurysm awareness, research, support, education, advocacy, and is the largest private funder of brain aneurysm research, as per a press release.
Maier will join the board of directors to serve the brain aneurysm community in increasing medical experts’ and the general public’s understanding of the early warning signs of brain aneurysm—a disease that is often misdiagnosed.
“I am honoured to join the board of directors of this wonderful organisation that has done so much for those who have been or will be impacted by brain aneurysms,” said Maier. “Nearly 30,000 people each year suffer a ruptured brain aneurysm, often resulting in tragic outcomes. BAF’s decades of diligent work to educate the public and spread awareness about the critical nature of brain aneurysms is incredibly important and close to my heart.”
Maier has served as RapidAI’s vice president of Clinical Affairs since 2018, leading the development and implementation of clinical protocols for the company’s artificial intelligence (AI) technology to improve the detection, measurement, and management, of life-threatening conditions like brain aneurysms.
Prior to joining RapidAI, she worked with the Stanford University School of Medicine’s Department of Neurosurgery (Stanford, USA) as a senior research scientist for several years.
